The ADC market

The first antibody drug conjugate (ADC) was approved in 2000 by pairing a cytotoxic chemotherapy agent with the targeting abilities of a monoclonal antibody, and the market has been on quite the journey since then. More than 20 years and many technical and safety challenges later, the field is still relatively early in its evolution yet is now recognized as one of the most promising and fastest-growing segments in oncology.

As of May 2026, there are approximately 23 ADC biopharmaceutical products approved globally and many more in late-stage clinical trials. According to GlobalData, 93 Phase III clinical trials were initiated for ADCs in 2025, compared to 67 in 2024 and 31 in 2023. Last year, the market was valued at around $20 billion and is expected to reach $60 billion by 2030. Statistics like these highlight the rapid expansion of ADCs, while a quick glance at the pipeline – revealing 412 different programs in various stages of clinical trials – illustrates the magnitude of the field.

Source: GlobalData

This growth is not just about volume but diversification. New targets, novel payload strategies, and combination therapies are expanding the scope of ADCs well beyond their original applications. In research settings, the potential of ADCs is even being explored for non-oncology indications such as autoimmune diseases, viral infections, and neurological disorders. In oncology, meanwhile, the market is becoming more dynamic, with frequent new market approvals, label expansions, and evolving treatment paradigms. ADCs initially approved for advanced cancers are now being studied and adopted across broader tumor types and earlier stages of treatment, reflecting their expanding role in modern oncology care.

Secondary packaging challenges

ADCs require sophisticated packaging technologies, processes, and expertise to meet the dual requirements of both biologics and potent small-molecule payloads. As new ADCs are introduced to market, there has been a significant increase in the reliance on contract development and manufacturing organizations (CDMOs) and contract packaging organizations (CPOs), which have already invested in the specialized containment systems, enhanced operator safety protocols, and rigorous environmental controls needed to safely handle ADCs.  

“Secondary packaging activities are a critical component of the product’s overall control strategy,” says Jeff Benedict, CCO, Sharp. “Packaging processes must ensure protection from contamination and degradation, provide accurate and compliant labeling, and facilitate safe handling of hazardous materials.”

On top of this, stability is a key concern for the biologically active component of the ADC, with secondary packaging and handling processes helping to protect the drug from temperature, humidity, and light. With any deviations risking significant implications for product and human safety, packaging must be robust and highly validated. Yet at the same time, the latest ADC trends emphasize the need for agility and scalability.

“Many ADCs are launched with relatively small, indication-specific patient populations and then expand over time as new indications are approved,” explains Benedict. “This demands a specialist ‘high mix-low volume’ packaging environment capable of supporting small batch production, frequent changeovers, and evolving label and configuration requirements — adding significant operational complexity.”

Agility is crucial in this environment, he emphasizes. Packaging operations must efficiently accommodate multiple SKUs while maintaining compliance. For pharmaceutical companies, partnering with a commercial packaging partner that can adapt to changing demand as the therapies expand across indications and global markets is critical to sustained success.